Needham Initiates Coverage On iRadimed with Hold Rating
Needham analyst David Saxon initiates coverage on iRadimed (NASDAQ:IRMD) with a Hold rating.
Share
Why It Matters
A big research firm just started watching iRadimed and gave it a 'hold' grade. That means they think the stock is okay but not exciting right now.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.